- Governments Must Act to Avoid More Dubais: El-Erian
- Regulators Compile Global List of 'Systemic Risk' Banks
- Dubai Stocks Shed 7%, Abu Dhabi Tumbles 8%
- The World's Biggest Debtor Nations
- UAE, Abu Dhabi Ratings Unlikely to Be Cut: Moody's
- US Midwest Business Expands Stronger Than Expected
- BofA Aims to Clearly Spell Out Credit Card Terms
- Advertisers Sticking With Tiger After Accident
- What Black Friday Shoppers Spent on – And Where
- November Winners & Losers
- Farrell: Testing Those International Waters Again
- Bob Doll: “We Continue to See Gains”
- My Commodities Outlook after Dubai: Dennis Gartman
- Saab Lovers Sound Off
- Tiger Ads Continue To Run Today
- Cheap Gas, Cheap Gifts
- Diving Partridge Demand Can't Keep Lid on '12 Days' Cost
- Tamminen: Copenhagen And Beyond
MOST SHARED
- Dubai Stocks Shed 7%, Abu Dhabi Tumbles 8%
- Tiger Woods Wants to Protect Family Privacy: Agent
- Governments Must Take Steps To Avoid More Dubais: El-Erian
- Dubai's Nakheel Seeks Suspension $5.25 Billion in Bonds
- South Korea Sees Exports Bouncing, but Risks Remain
- US Shoppers Spent Less Over Black Friday: NRF
- US Senator Opposes Fed Chief Bernanke Renomination
- Sands China Ends 10.2% Lower in Hong Kong Debut
- Tamminen: Copenhagen And Beyond
Text Size 
Shares of CV Therapeutics plummeted [CVTX
Loading...
()
] following the company's announcement late Tuesday that its angina drug ranolazine was not effective in a study of acute and long-term treatment of patients with a type of heart disease known as acute coronary syndrome.
Wednesday's drop came on top of the shares losing more than a quarter of their value in after-market trading Tuesday.
There was no adverse trend in death or arrhythmias in patients taking the drug, also known by the chemical name ranolazine, the company said.
CV Therapeutics said it believes the data could support expansion of the drug's approved uses to be included as a first choice treatment for angina. It is currently approved to treat chronic angina in patients who have not achieved an adequate response with other drugs.
Print
Email
- Ever wished your cab driver would stop chatting and just get to where you're going? Well, that moment is closer than ever.
- With Americans cutting back on spending, holiday tipping will take another hit this year.
- From the why-didn’t-I-think-of-that file, we present Jason Sadler, a man whose job is wearing T-shirts.
- Shopping for a gadget hound? The choices can be baffling. Here are a few that should be a hit.
- "The Who" will be the halftime act for Super Bowl XLIV on Feb. 7 in Miami. Is the NFL behind the times?
- Zhu Zhu Pets are this year's must-have toy, fetching $40 or more on eBay.
Data is a real-time snapshot *Data is delayed at least 15 minutes